Effectiveness of periprostatic block to prevent pain in transrectal prostate biopsy: a systematic review and a network meta-analysis

Herney Andres Garcia-Perdomo, Natalia Guzman Mejia, Lizeth Fernandez, Jorge Carbonell

School of Medicine, Department of Urology, Universidad del Valle, Cali, Colombia

Introduction
The purpose of this study was to determine the effectiveness and harms of periprostatic block compared with other interventions in patients with clinically suspected prostate cancer who underwent transrectal biopsy to diminish pain.

Material and methods
We included only clinical trials which involved male adults older than 18 years-old suspected of having prostate cancer. The intervention performed was a periprostatic block and the comparators were topical anesthetics, sedatives, placebo/no intervention or combined therapies. The primary outcome was perianal or perineal pain and serious adverse effects (SAE). Literature search was conducted in MEDLINE, EMBASE, LILACS, CENTRAL and non-published literature from inception to March 2019. We performed a network meta-analysis in R.

Results
We included 43 studies in the meta-analysis. Thirteen studies compared periprostatic block vs. placebo/no intervention (the most frequent). Most of the studies had an unclear risk of bias for selection, performance and detection bias and low risk for attrition, reporting and other bias. Periprostatic block (lidocaine) + intrarectal gel (lidocaine + prilocaine) vs. periprostatic block (lidocaine) showed an RR -0.9 (95%CI – 1.9 to 0.074); intrarectal gel (lidocaine) vs. periprostatic block (lidocaine) had a RR 0.77 (95%CI 0.14 to 1.4); placebo/no intervention vs. periprostatic block (lidocaine) + intrarectal gel (lidocaine+prilocaine) RR 3 (95%CI 1.9 to 4); intrarectal gel (lidocaine) versus periprostatic block (lidocaine) + intrarectal gel (lidocaine + prilocaine) RR 1.7 (95%CI 0.64 to 2.7).

Conclusions
The blockage of the periprostatic plexus in the performance of a transrectal ultrasound-guided prostatic biopsy, alone or in combination with intrarectal analgesia or sedation, is an effective method to reduce pain.

INTRODUCTION
More than 1.1 million cases of prostate cancer (PCa) cases were registered per year during the last few years, which represents around 8% of new cases and 15% in men all over the world [1]. PCa is the second leading cause of cancer-specific death in the United States and it is estimated that during the following years 26,120 new deaths will be caused by this condition [2]. Nowadays, more than 90% of PCa cases are diagnosed in the early stages, which get higher 5 year-overall survival (almost 100%) [2]. This is generally suspected by an abnormal digital rectal examination and/or an elevated prostate-specific antigen (PSA) [3]. Early detection might significantly reduce related morbidity and increase survival of these patients, this is why urologists need to diagnose and initiate treatment faster to increase the probability of a successful outcome [4, 5].
Regarding the diagnosis, the prostate biopsy is the gold standard to make the diagnosis and we have two different approaches to perform this procedure: transperineal and transrectal. The latter is the most commonly used nowadays [6]. Although transrectal ultrasound-guided (TRUS) prostatic biopsy has been considered a minor procedure, people often experience pain, anxiety and disturbances before, during and after the procedure [7]. About 65–90% of men experience pain based on different factors: entering an ultrasound probe in the rectum, the movement of this device, size and geometry of the probe, the insertion of the needle for injecting anesthetics, the biopsy itself, among others [6, 7, 8].

Pain is the most important problem during this procedure and there are lots of approaches to reduce it and to improve adaptation of these patients; however, there is no consensus about what to choose [9]. The European Association of Urology recommend topical anesthesia plus periprostatic nerve bundle block (PPNB) [10]; however, there are multiple trials considering other approaches like a single PPNB, only topical gels, combined therapies, among others, additionally, there is some evidence supporting that the most painful moment is the application of the anesthetic [10, 11].

Based on literature, there is no standard of care to this approach and selection depends mainly on clinical condition, experience of the physician and clinical criteria, furthermore, we considered a systematic review to try to elucidate this problem. The purpose of this systematic review was to determine the effectiveness and harms of periprostatic block compared with other interventions in patients with clinically suspected prostate cancer who undergo transrectal biopsy to diminish pain during and after the procedure.

MATERIAL AND METHODS

We performed this review according to the recommendations of the Cochrane Collaboration and following the PRISMA Statement. The PROSPERO registration number is CRD42018094806.

Inclusion criteria

We included only clinical trials which involved male adults over 18 years-old suspected of having prostate cancer based on any of the clinical or biochemical indications and who underwent transrectal prostate biopsy according to standard procedure. The intervention was periprostatic block (injecting an anesthetic solution (bupivacaine 0.25%, lidocaine 1–2% or articaine 1%) on neurovascular bundles on each side of the prostate gland, this has to be guided by ultrasound and identifying the correct position by a hypoechoic bubble) and the comparators were topical anesthetics, sedatives, placebo/no intervention or combined therapies [12, 13].

The primary outcome was perianal or perineal pain (assessed by any validated tool i.e. visual analogue scale (VAS) and serious adverse effects (SAE) (fever, rectal bleeding >2 days, prostatitis and acute urinary retention) [14]. Secondary outcomes were other adverse effects (hematospermia, hematuria, rectal bleeding less than two days) [2]. There were no setting or language restrictions. The exclusion criteria were: transperineal biopsy and other conditions that might increase or produce pain during the biopsy.

Information sources

Literature search was conducted in accordance to the recommended procedure by Cochrane. We used medical subject headings (MeSH), Emtree language, DeCS and text words related in a complete search strategy (Appendix 1). We searched MEDLINE (OVID), EMBASE, LILACS and the Cochrane Central Register of Controlled Trials (CENTRAL) from inception to March 2019. To ensure literature saturation, we scanned references from relevant articles identified through the search, conferences, thesis databases, Open Grey, Google scholar and clinicaltrials.gov, among others. We contacted authors by e-mail in case of missing information.

Data collection

We reviewed each reference by title and abstract. Then we scanned full-texts of relevant studies, applied pre-specified inclusion and exclusion criteria and then extracted the data. Disagreements were resolved by consensus and where disagreement could not be solved, a third reviewer was used to dissolve the conflict.

Relevant data were collected in duplicate by using a standardized data extraction sheet that contained the following information: author names, year of publication, title, study design, geographic location, objectives, inclusion and exclusion criteria, number of patients included, losses to follow-up, timing, definition of outcomes (infection), outcomes and association measures and funding source.

Risk of bias

The assessment of the risk of bias for each study was made using the Cochrane Collaboration tool for assessing the risk of bias, which covers: sequence generation, allocation concealment, blinding, incomplete outcome data, selective reporting and other biases.
We judged the possible risk of bias from extracted information, rated as ‘high risk’, ‘low risk’ or ‘unclear risk’. We computed a graphic representation of potential bias using RevMan 5.3.

Data analysis / synthesis of results

We performed the statistical analysis in R [15] with the command gemtc for a Bayesian network meta-analysis and Review Manager v5.3. For outcomes we reported information about risk differences (RD) with 95% confidence intervals according to the type of variables and we pooled the information with a fixed effect network meta-analysis according to the heterogeneity expected. The results were reported in forest plots of the estimated effects of the included studies with a 95% confidence interval (95% CI). Heterogeneity was evaluated using the I2 test. For the interpretation, it was determined that the values of 25%, 50%, and 75% in the I2 test corresponded to low, medium, and high levels of heterogeneity, respectively. Assumption of transitivity was plausible and evaluated according to the kind of comparisons and considering the similarity of the distribution of the potential effect modifiers across the different pairwise comparisons. Additionally, for every treatment, we estimated the probability of being at each possible rank to infer the relative ranking of the treatments.

Publication bias

An evaluation was conducted to identify reporting or publication bias using the funnel plot.

Sensitivity analysis

We performed sensitivity analysis extracting weighted studies and running the estimated effect to find differences.

Geometry of the network

We produced network diagrams to show the amount of evidence available for each outcome and the most frequent comparison. The size of the nodes was proportional to the total number of patients allocated to the treatments across all trials and the width of the lines was proportional to the total number of RCTs evaluating the comparisons.

Assessment of inconsistency

We evaluated consistency using the node-splitting model through a Bayesian network meta-analysis.

Subgroup analysis

We tried to perform subgroup analysis based on: age, geographical setting and kind of biopsy, but the information was similar on some variables and so dissimilar in other, therefore we decided against performing it.

RESULTS

Study selection

We found a total of 1299 studies with the search strategies and after eliminating 143 duplicates and those based on title and abstract screening, we finally included 43 studies [10, 16–57] in the qualitative analysis. We produced network diagrams to show the amount of evidence available for each outcome and the most frequent comparison. The size of the nodes was proportional to the total number of patients allocated to the treatments across all trials and the width of the lines was proportional to the total number of RCTs evaluating the comparisons.

Figure 1. Flowchart.
and quantitative analysis (Figure 1). We updated the search to March 2019 and found 120 additional files, but none of them were relevant to this study (Excluded by title/abstract).

**Characteristics of included Studies**

A total of 5,885 patients with a mean of 137 patients per study (range 40–430) were included. Seven studies used placebo as the only comparator [16, 19, 20, 29, 44, 45, 52], while five used no intervention as the comparator [17, 21, 33, 42, 55]. The indication of biopsy was not clearly described in one single article [51] and the most common indication was an abnormal PSA levels and/or suspicious digital rectal exam (DRE) [10, 16–57]. For the evaluation of the results, all the studies used an analogous scale of pain (VAS) that ranges between 0–10 [10, 16–54, 56, 57]. The time for the most frequent outcome evaluation was immediately after the biopsy, which was performed in twenty-six studies [17–27, 29–31, 33, 36, 39, 40, 45, 47, 48, 50, 51, 53, 54, 56]. Thirteen studies have a result evaluation during the biopsy [10, 25, 32, 34, 37, 41–44, 49, 52, 55, 57], two studies at 15 minutes after the biopsy [16, 46], one study during the insertion of the needle [38], another study 20 minutes after [35] and one 30 minutes after of biopsy [28] (see Table 1).

**Summary of network geometry**

Placebo/no intervention vs. periprostatic block only was the most frequent comparison, it was found in 13 studies [16–21, 29, 33, 42, 44, 45, 52, 55]. We found nine studies with the comparison between intrarectal gel (lidocaine) vs. periprostatic block (lidocaine) [18, 27, 28, 35, 40, 47, 53, 54, 57] and seven studies with intrarectal gel (lidocaine) vs. placebo/no intervention [22, 23, 30, 34, 39, 41, 56].

Two studies followed the comparison with intrarectal gel (lidocaine) vs. periprostatic block (lidocaine) + intrarectal gel (lidocaine + prilocaine) [47, 54], while four studies used periprostatic block (lidocaine) + intrarectal gel (lidocaine + prilocaine) vs. periprostatic block (lidocaine) [10, 35, 50, 51].

Three studies had the following comparisons: 1. placebo gel vs. periprostatic block (lidocaine); 2. sedative vs. periprostatic block (lidocaine); 3. placebo/no intervention vs. periprostatic block (lidocaine) + intrarectal gel (lidocaine + prilocaine); 4. intrarectal gel (lidocaine) vs. placebo gel; 5. sedative vs. placebo/no intervention (see Figure 2).

Yun 2016 was excluded from the network analysis since it had only one arm.

**Risk of bias**

All of the studies were classified as low risk of bias in the following issues: incomplete outcome data, selective reporting and other bias. On the contrary, we found mostly unclear risk of bias in: random sequence generation, allocation concealment, blinding of participants and personnel and blinding of outcome assessment.

Stirling 2002, Stirling 2002a and Szlauer 2008 [21, 23, 40] had high risk of bias in blinding of participants and personnel since they had incomplete masking, while some groups were aware of intervention. Wu 2001 [52], had a high risk of bias in the random sequence generation since it had randomization based on inappropriate tools.

Studies like Addla 2003, Kravchick 2005, Lynn 2002 and Ragavan 2005 were classified as high quality (low risk of bias) since they only had one issue on the unclear risk of bias [19, 22, 31, 32] (see Figure 3).

**Exploration for inconsistency and ranking**

For the primary outcome and the node-splitting model we found that the following comparisons were consistent, but some of them were heterogeneous: periprostatic block A (lidocaine injection) versus combined ([periprostatic block (lidocaine) + intrarectal gel (lidocaine + prilocaine)] (I2 = 99%; inconsistency p value = 0.12); periprostatic block A versus topical (intrarectal gel [lidocaine]) (I2=99%; inconsistency p value = 0.38); combined versus placebo / no intervention (I2 = 45%; inconsistency
### Table 1. Characteristics of included studies

| Study                        | No. of patients | Participants                                                                 | Intervention 1                                      | Intervention 2      | Intervention 3                                      | Intervention 4                                      | Outcome assessment                  |
|------------------------------|-----------------|------------------------------------------------------------------------------|----------------------------------------------------|---------------------|----------------------------------------------------|----------------------------------------------------|-------------------------------------|
| Ozeri et al. (2003) [16]     | 100             | Men, elevated total prostate-specific antigen (tPSA) and/or abnormal digital rectal examination (DRE) | Periprostatic block (Lidocaine) Periprostatic block (Lidocaine) Placebo |                     |                                                    |                                                    | 15 min after the procedure          |
| Walsh et al. (2003) [17]     | 64              | Abnormal DRE or an elevated PSA                                              | Periprostatic block (Lidocaine) No intervention | No intervention     |                                                    |                                                    | Immediately                        |
| Rodriguez et al. (2003) [18] | 96              | Abnormal prostate on digital rectal examination and/or elevated serum prostate specific antigen PSA, some patients have re-biopsy because of a prostatic intraepithelial neoplasia history (PIN), a continuous raised PSA level and a diagnosed cancer in previous prostate resection | Intrarectal gel (Lidocaine) Periprostatic block (Lidocaine) |                     |                                                    |                                                    | Immediately                        |
| Addla et al. (2003) [19]     | 98              | Prescriptions were requested on a named patient basis at the beginning of each TRUS biopsy list | Periprostatic block (Lidocaine) Placebo           |                     |                                                    |                                                    | Immediately                        |
| Berger et al. (2003) [20]    | 100             | Men suspected of having prostate cancer Subjects were included a normal age-specific prostate-specific antigen (PSA) | Periprostatic block (Lidocaine) Placebo           |                     |                                                    |                                                    | Immediately                        |
| Rodriguez et al. (2002) [21] | 96              | Abnormal DRE or an elevated PSA                                              | Intrarectal gel (Lidocaine) Periprostatic block (Lidocaine) |                     |                                                    |                                                    | Immediately                        |
| Stirling et al. (2002) [22]  | 100             | Referred for transrectal ultrasound from who informed consent was obtained were eligible | No intervention Periprostatic block (Lidocaine) |                     |                                                    |                                                    | Immediately                        |
| Lynn et al. (2002) [23]      | 86              | Abnormal PSA level (>4 ng/mL) and/or an abnormal DRE, and prostatic biopsy for the first time | Periprostatic block (Lidocaine) Intrarectal gel (Lidocaine) Placebo gel Placebo |                     |                                                    |                                                    | Immediately                        |
| Stirling et al. (2002) [24]  | 150             | Men requiring biopsy of the prostate                                          |                     | No intervention Intra rectal gel (Lidocaine) | Periprostatic block (Lidocaine) |                                                    |                                                    | Immediately                        |
| Hiros et al. (2010) [25]     | 90              | Abnormal PSA level (>4 ng/mL) and/or an abnormal DRE, and prostatic biopsy for the first time | Periprostatic block (Lidocaine) Intrarectal gel (Voltaren) |                     |                                                    | Placebo gel |                                                    | Immediately                        |
| Kim et al. (2011) [26]       | 430             | Patients who visited the department of urology                              | Periprostatic nerve block with 1% lidocaine Acetaminophen 650 mg, |                     |                                                    |                                                    | EMLA cream During biopsy            |
| Song et al. (2004) [27]      | 90              | Abnormal DRE, level PSA>4 ng                                               | Intra rectal gel (Lidocaine) Periprostatic block (Lidocaine) Placebo |                     |                                                    |                                                    | Immediately                        |
| Yun et al. (2006) [28]       | 250             | Increased PSA with or without abnormal digital rectal examination, 2) with lesion suspected malignancy on TRUS | Lidocaine gel intrarectal+PNB Perianal block (Lidocaine) |                     |                                                    |                                                    | Lidocaine gel intrarectal gel (Lidocaine) | During biopsy                        |
| Manikandan et al. (2003) [29] | 235             | Abnormal PSA levels and/or suspicious DRE                                   | No intervention Periprostatic block (Lidocaine) Periprostatic block (Lidocaine) + Intrarectal gel (Lidocaine) |                     |                                                    |                                                    | Tramadol infused intravenously in 30 minutes at a dose of 1.5 mg/kg in 100 cc saline | Immediately                        |
| Obek et al. (2004) [30]      | 300             | Abnormal PSA levels and/or suspicious DRE                                    | No intervention Periprostatic block (Lidocaine) |                     | Periprostatic block (Lidocaine) + Intrarectal gel (Lidocaine) |                                                    |                                                    | Immediately                        |
Table 1. Continuation

| Study                      | No. of patients | Participants                                                                 | Intervention 1 | Intervention 2 | Intervention 3 | Intervention 4 | Outcome assessment |
|----------------------------|-----------------|------------------------------------------------------------------------------|----------------|----------------|----------------|----------------|--------------------|
| Mallick et al. (2004) [28] | 328             | Abnormal digital rectal prostate examination or transrectal ultrasound scan and/or elevated prostate specific antigen (PSA) (greater than to 4 ng/ml). | Intrarectal gel (Lidocaine) | Periprostatic block (Lidocaine) |                        |                | 30 min             |
| Vanni et al. (2004) [29]   | 40              | Elevated PSA levels and/or suspicious DRE                                    | Periprostatic block (Lidocaine) | Placebo |                        |                | Immediately       |
| Trucchi et al. (2005) [30] | 60              | Elevated prostate-specific antigen (PSA) level and its derivates (total and free PSA, free/total PSA ratio, PSA density, PSA velocity), abnormal digital rectal examination (DRE), abnormal transrectal sonography | No intervention | Intrarectal gel (Lidocaine) | Periprostatic block (Lidocaine) |                | Immediately       |
| Kravchick et al. (2005) [31]| 114             | Abnormal digital rectal examination findings and/or an elevated prostate-specific antigen (PSA) level (4 ng/mL or greater) | Intrarectal gel (Lidocaine) | Intrarectal gel (DMSO + Lidocaine) | Periprostatic block (Lidocaine) | Periprostatic block (Lidocaine) | Immediately       |
| Ragavan et al. (2005) [32] | 165             | Increased prostate specific antigen (PSA) with or without abnormal digital rectal examination | Periprostatic block (Lidocaine) | Diclofenac suppository | Periprostatic block (Lidocaine) | Periprostatic block (Lidocaine) + Diclofenac suppository | During biopsy     |
| Feltes Ochoa et al. (2006) [33] | 131 | Abnormal PSA level (>4 ng/mL) and/or an abnormal DRE | Periprostatic block (Bupivacaine) | No intervention | Placebo |                        |                | Immediately       |
| Song et al. (2006) [34]    | 90              | Abnormal digital rectal examination and/or serum prostate-specific antigen (PSA) concentrations of 4 ng/mL or higher. | Intrarectal gel (Lidocaine) | Periprostatic block (Lidocaine) |              | placebo | During biopsy     |
| Yun et al. (2007) [35]     | 250             | Abnormal finding during the digital examination and/or elevated serum PSA levels higher than 2.5 ng/mL | No intervention | Periprostatic block (Lidocaine) | Intrarectal gel (Lidocaine) | Sedative (Midazolam + Fentanyl) | Immediately |
| Giannarini et al. (2009) [10]| 280          | Increased serum PSA (4 ng/ml or greater), and/or abnormal digital rectal examination or TRUS findings | Periprostatic block (Lidocaine) + Intrarectal cream (Lidocaine + Prilocaine) | Periprostatic block (Lidocaine) | No intervention | Placebo | During biopsy |
| Izol et al. (2012) [36]    | 100             | Abnormal finding during the digital examination and/or elevated serum PSA levels higher than 2.5 ng/mL | No intervention | Periprostatic block (Lidocaine) | Intrarectal gel (Lidocaine) | Sedative (Midazolam + Fentanyl) | Immediately |
| Lunacek et al. (2014) [54] | 123             | People with suspected PCA without active prostatitis underwent TRUS-guided biopsy | Intrarectal gel (Lidocaine) | Periprostatic block (Lidocaine) | Periprostatic block (Lidocaine) + Intrarectal gel (Lidocaine) |                | Immediately       |
| Griwan et al. (2012) [37]  | 60              | Patients with elevated prostate-specific antigen (PSA) levels (>4 ng/mL) and abnormal results on digital rectal examination (DRE), Diclofenac patch 100mg | Periprostatic block (Lidocaine) | Periprostatic block (Lidocaine) | No intervention | Placebo | During biopsy |
| Ozok et al. (2010) [38]    | 100             | Patients with prostate-specific antigen (PSA) above the level of 2.5 ng/ml and/or with abnormal digital rectal examination (DRE) findings were included in the study | Periprostatic block (Lidocaine) | Periprostatic block (Lidocaine) + Tramadol hydrochloride 50 mg | Periprostatic block (Lidocaine) + Intramuscular Midazolam | Placebo | Pain during needle |
### Table 1. Continuation

| Study                        | No. of patients | Participants                                                                 | Intervention 1                                      | Intervention 2                                         | Intervention 3                                      | Intervention 4                                      | Outcome assessment |
|------------------------------|-----------------|-------------------------------------------------------------------------------|-----------------------------------------------------|-------------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|--------------------|
| Sataa et al. (2010) [39]     | 100             | Less than 70 years of age and in whom prostate biopsy was indicated for a prostate suspected malignancy to the rectal examination and / or an increase in the level of the specific antigen prostate (PSA) >3 ng/ml | Intrarectal gel (Lidocaine)                         | Periprostatic block (Lidocaine)                       | Placebo gel                                        | –                     | Immediately        |
| Szlauer et al. (2008) [40]   | 100             | Indications for prostate biopsy included an abnormal digital rectal examination and/or an increased serum PSA level | Intrarectal gel (60 mg lidocaine 2h)                | Intrarectal gel (120 mg lidocaine 1h)                  | Intrarectal gel (120 mg lidocaine 2h)               | Periprostatic block (Lidocaine)                       | Immediately        |
| Raber et al. (2008) [41]     | 300             | Abnormally elevated prostate-specific antigen (PSA) levels or suspicious digital rectal exam (DRE) results | Periprostatic block (Lidocaine)                     | Periprostatic block (Lidocaine) + Intrarectal gel (Lidocaine) | Placebo                                             | During biopsy                |                    |
| Jones et al. (2003) [42]     | 60              | Men requiring biopsy of the prostate                                          | Periprostatic block (Lidocaine)                     | No intervention                                      |                                                    |                                                      |                    |
| Turgut et al. (2006) [3]     | 93              | Suspicious digital rectal examination (DRE), abnormally elevated serum prostate-specific antigen (PSA) level or abnormal TRUS findings referred | Sedative (Midazolam)                                | Periprostatic block (Lidocaine)                       | No intervention                                    |                                                      | Immediately        |
| Raber et al. (2008) [41]     | 73              | Abnormal prostate on digital rectal examination and/or elevated prostate specific antigen (PSA) > 4 ng/ml | Periprostatic block (Lidocaine)                     | Placebo                                              |                                                      |                                                      | Immediately        |
| Jones et al. (2003) [42]     | 126             | Abnormal digital rectal examination (EDR) and/or elevated prostate specific antigen (PSA) | Periprostatic block (Lidocaine)                     | No intervention                                      |                                                      |                                                      | Pain following biopsy |
| Nambirajan et al. (2004) [45]| 96              | Abnormal digital rectal examination (DRE) or elevated PSA                    | Periprostatic block (Lidocaine)                     | Placebo                                              |                                                      |                                                      | Immediately        |
| Gurbuz et al. (2010) [46]    | 100             | Elevated prostate-specific antigen (PSA) levels                             | No intervention                                     | Perianal block (Lidocaine)                           | Periprostatic block (Lidocaine) + Intrarectal cream (Lidocaine + Prilocaine) | 15 min               |                    |
| Park et al. (2005) [47]      | 61              | Patients with a negative pathology after an initial sextant biopsy, with no sedatives or analgesia, were rebiopsied using the 12 extended biopsy technique. | Periprostatic block (Lidocaine) + Intrarectal gel (Lidocaine) | Perianal block (Lidocaine)                           | Periprostatic block (Lidocaine) + Intrarectal gel (Lidocaine) | –                     | Immediately        |
| Basar et al. (2005) [48]     | 80              | Patients with elevated prostate-specific antigen (PSA) levels but with prostate nodules on digital rectal examination (DRE) were included | Placebo cream (Lidocaine + Prilocaine)              | Intrarectal cream (Lidocaine + Prilocaine)           | Periprostatic block (Lidocaine)                     | Periprostatic block (Lidocaine)                       | Immediately        |
| Cantiello et al. (2009) [49] | 200             | Abnormal DRE findings, or an increased PSA level with or without abnormal DRE findings, or lesions suspicious for malignancy on TRUS with or without an abnormal DRE | Periprostatic block (Lidocaine + Naropine)         | Periprostatic block (Antroline)                      | Periprostatic block (Lidocaine + Intrarectal gel (Lidocaine + Prilocaine)) | –                     | During biopsy       |
| Kumar et al. (2012) [50]     | 240             | All patients with indication for biopsy                                       | Periprostatic block (Lidocaine)                     | Intrarectal cream (Lidocaine + Prilocaine)           | Periprostatic block (Lidocaine) + Intrarectal gel (Lidocaine + Prilocaine) | –                     | Immediately        |
p value = 0.74); combined versus topical (I2 = 99%; inconsistency p value = 0.35); placebo gel versus placebo / no intervention (I2 = 0%; inconsistency p value = 0.33); placebo / no intervention versus topical (I2 = 90%; inconsistency p value = 0.18); sedative versus topical (I2 = 21%; inconsistency p value = 0.3) (Table 2). Ranks were higher for placebo and topical interventions (see Figure 4).

**Outcome: pain**

After running the Bayesian Network meta-analysis, we found that the periprostatic block (lidocaine), combined therapy [periprostatic block (lidocaine) + intrarectal gel (lidocaine + prilocaine)]; periprostatic block (lidocaine) + tramadol hydrochloride 50 mg; sedative and intrarectal gel (lidocaine) lowered the pain when compared with placebo. Additionally, any kind of placebo and intrarectal gel increased the pain when compared with the periprostatic block (lidocaine) (Figure 5).

**Mixed treatment comparisons**

As we stated before, the following comparisons were consistent on the network. For the comparisons: periprostatic block A versus topical [intrarectal gel (lidocaine)] and combined versus topical, we found that topical intervention increases pain. Similar to the placebo in the comparison: combined versus placebo / no intervention. On the otherside, there was decreased pain for the topical in the comparison: placebo/no intervention versus topical (see Table 2). There were no significant differences for the other comparisons.

**Secondary outcomes**

The secondary results obtained included adverse effects defined as fever, rectal bleeding >2 days, prostatitis, urinary retention and death [27]. The following studies reported some of these events.

In the studies comparing periprostatic plexus block vs. placebo [16, 20], intrarectal gel vs. periprostatic plexus block vs. placebo and the study of intrarectal gel vs. periprostatic plexus block vs. placebo, fever was not reported as an adverse event during the follow-up period. In the study of placebo intrarectal cream vs. intrarectal cream vs. periprostatic plexus block [48] and in periprostatic block vs. intrarectal gel (Voltaren) vs. intrarectal gel placebo, no serious adverse events were reported [24].

In the study where the groups non-intervention vs. periprostatic plexus block vs. periprostatic plexus block in combination with intrarectal gel vs. tramadol infusion were compared, the following were reported in intervention group 1:1 fever event; group two: 1 event of urinary retention; and group three: one event of fever and six events of urinary retention [27].

In the study of intrarectal gel (lidocaine) vs. intrarectal gel (DMSO + lidocaine) vs. perianal block vs. periprostatic block without specification of belonging to a specific intervention, it was reported that 10 days after the biopsy, two patients presented with fever, and there was one urinary retention event [31].

In the comparison the study between periprostatic plexus block vs. intrarectal diclofenac suppository

---

**Table 1. Continuation**

| Study                        | No. of patients | Participants                                                                 | Intervention 1                                | Intervention 2                  | Intervention 3                                  | Intervention 4 | Outcome assessment |
|------------------------------|-----------------|--------------------------------------------------------------------------------|-----------------------------------------------|---------------------------------|-------------------------------------------------|----------------|-------------------|
| Dalva et al. (2013) [51]     | 90              | NA                                                                             | Perianal lidocaine-prilocaine cream (EMLA, 5 gr) + periprostatic nerve block lidocaine | Periprostatic block (Lidocaine) | Periprostatic block (Lidocaine) | Placebo | Immediately       |
| Wu et al. (2001) [52]        | 40              | All patients had laboratory indications for prostate biopsy (eg, elevated PSA level of 4.0 indications for prostate biopsy (eg, elevated PSA level of 4.0 | Periprostatic block (Lidocaine) | Placebo | Placebo | During biopsy |

---

**Figure 3A. Risk of bias within studies.**
vs. periprostatic plexus block in combination with diclofenac suppository, fever occurred in 1, 2 and 0 patients, respectively, in each intervention [32]. In the block of periprostatic plexus vs. intrarectal gel vs. placebo, intervention group 1 presented with
lished to date in which we attempted to determine the efficacy of periprostatic block to prevent pain in transrectal prostate biopsy. We performed multiple comparisons between the analgesic therapies used to relieve pain during transrectal prostate biopsy. Our findings showed that any type of intervention was significantly superior to the placebo to prevent pain. In addition, our results showed that patients undergoing transrectal prostatic biopsy with periprostatic block or combination therapy (periprostatic block + intrarectal gel) had significantly lower pain scores than patients treated only with topical intervention (intrarectal gel). Intrarectal gel and periprostatic block did not show significant differences.

In contrast with these results, certain published randomized controlled trials (RCTs), such as Ingberg in 2010, supported the idea that the pain experienced during transrectal prostate biopsy was mild and did not decrease significantly with periprostatic block, and they noted that the pain of the injection itself was similar to the pain of the biopsies. They

three events of fever and urinary retention; intervention group 2: two events of fever; and intervention group 3: two events of fever and urinary retention [41].

In the comparison of periprostatic plexus block vs. placebo, the placebo group presented with one infection event without specification that required hospital admission [45].

In the intervention study of periprostatic plexus block in combination with intrarectal gel vs. placebo vs. intrarectal gel, there was one event of urinary retention in group 1; none of the groups presented fever [47].

Finally, in the comparison of periprostatic plexus block (lidocaine + naropin) vs. periprostatic plexus block (antrolin), there was one event of urinary retention and fever in both groups [49].

**DISCUSSION**

To our knowledge, this is the first systematic review and online meta-analysis of clinical trials published to date in which we attempted to determine the efficacy of periprostatic block to prevent pain in transrectal prostate biopsy. We performed multiple comparisons between the analgesic therapies used to relieve pain during transrectal prostate biopsy. Our findings showed that any type of intervention was significantly superior to the placebo to prevent pain. In addition, our results showed that patients undergoing transrectal prostatic biopsy with periprostatic block or combination therapy (periprostatic block + intrarectal gel) had significantly lower pain scores than patients treated only with topical intervention (intrarectal gel). Intrarectal gel and periprostatic block did not show significant differences.

In contrast with these results, certain published randomized controlled trials (RCTs), such as Ingberg in 2010, supported the idea that the pain experienced during transrectal prostate biopsy was mild and did not decrease significantly with periprostatic block, and they noted that the pain of the injection itself was similar to the pain of the biopsies. They
concluded that pain from transrectal prostate biopsy was well tolerated without requiring anesthesia [58] and Wu et al. did not find significant differences between the intervention groups with or without periprostatic plexus block with respect to VAS pain scores at any time [52]. However, some of the limitations of these studies include the size of the sample and the evaluation of pain at the actual moment of the procedure.

Supporting the results obtained in this review, different studies indicate that there are significant differences in the perception of pain during the transrectal prostate biopsy, which can be seen in the study by Ozvery et al., who found that approximately 50% of patients who were subjected to transrectal prostate biopsy who did not receive the injection of lidocaine as an intrarectal block had VAS pain scores ranging from moderate severity to intolerable. In 2011, Ozvery and Izol et al. demonstrated that patient comfort was better and that it was possible to obtain lower pain scores with periprostatic plexus block or sedoanalgesia. In 2003, Izol and Addla suggested that local anesthesia for TRUS biopsy was simple and well tolerated and could significantly reduce the pain associated with the procedure, recommending its use as part of the standard TRUS prostate biopsy [19, 36].

Among the strengths of our review was the quality of the search strategies designed for each database, which were specific for the detection of records related to the review, along with the inclusion of a sizeable number of available studies. However, some of the limitations are based on the risk of unclear bias regarding the generation of random sequences, concealment of allocation, blinding of participants and staff and blinding of the evaluation of results, which was not possible to determine in the complete review of the studies. This limitation does not necessarily indicate poor or good methodological quality. However, it could lead to an underestimation of quality because the best tool available to assess quality is the Cochrane Collaboration tool, which requires an appropriate report to properly stratify the studies. However, the studies generally had a low risk of bias with respect to incomplete outcome data, selective reporting and other biases.

Only three studies, Stirling 2002, Stirling 2002a and Szlauer 2008 [21, 23, 40], blinded the participants and staff; the others had incomplete masking, or some groups were aware of the intervention to which they were going to be submitted, which generated a high risk of blinding bias for these clinical trials.

Finally, this review was performed to answer a question related to a urological procedure commonly performed in clinical practice, based on pre-established and standardized indications, due to the indispensable diagnostic need, as PCa is a presently prevalent disease. Being such a useful procedure, it is important to ask the question about the acceptability or not of the procedure as a consequence of the pain inherent to this study. The pain associated with prostate biopsy is a complex phenomenon with psychosocial and physical attributes, which include the threshold of an individual's innate pain, pre-procedure anxiety, fear of a possible diagnosis of cancer and social inhibition towards the rectal exam [18], factors that could cause the patient to delay having the biopsy even, when its requirement is of vital importance.

Therefore, according to the findings in this review, we recommend the use of periprostatic block alone or in combination with topical intrarectal analgesia or sedation as part of the standard TRUS prostate biopsy. It should be noted that sedation as analgesia during the study is a field that has been little evaluated because of the ease of performing a periprostatic block in the ambulatory practice of biopsy, a method worthy of future studies.

Despite recommending this intervention, it is suggested to conduct clinical trials with larger samples and better methodological quality to improve the recommendations derived from this systematic review and meta-analysis.

CONCLUSIONS

Periprostatic plexus block in transrectal ultrasound-guided prostate biopsy, alone or in combination with intrarectal analgesia or sedation, is an effective method to reduce the pain inherent to the performance of the procedure in comparison with placebo or intrarectal analgesia alone. However, more high-quality trials are needed to support this conclusion and recommendation.

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.
References

1. International Agency for Research on Cancer. GLOBOCAN 2012 Cancer Incidence, Mortality and Prevalence Worldwide. 2013.

2. Mottet (Chair) N, Bellmunt J, Briers (Patient Representative) E, et al. Guidelines on Prostate Cancer. European Association of Urology. 2017.

3. National Comprehensive Cancer Network. NCCN Guidelines for Prostate Cancer. 2016.

4. Luan Y, Huang T, Gu X, et al. Effect of prostate volume on the peripheral nerve block anesthesia in the prostate biopsy: A strobe-compliant study. Medicine (Baltimore). 2016; 95: e4184.

5. Van den Bergh RCN, Loeb S, Roobol MJ. Impact of Early Diagnosis of Prostate Cancer on Survival Outcomes. Eur Urol Focus. 2015; 1: 137-146.

6. Agresott Guerra WA, Shek Padilla ÁH, Quiroga Matamoros W, Citarella Otero DA. Biopsia transrectal de próstata guiada por ecografía con 12 muestras de la zona periférica y muestras de la zona centro transicional en rebiopsias para el diagnóstico de cáncer de próstata. Rev Urol Colomb. Sociedad Colombiana de Urología. 2011; 20: 21-31.

7. Wang J, Zhou H, An W, Wang N, Gao Y. Effective Concentration of Lidocaine Plus Fentanyl for Caudal Block in Patients Undergoing Transrectal Ultrasound Guided Prostate Biopsy. Pain Res Treat. 2016; 2016: 5862931.

8. Yilmaz AH, Ziypak E, Ziypak T, et al. Combination of perianal-intrarectal lidocaine-prilocaine cream and periprostatic nerve block for pain control during transrectal ultrasound guided prostate biopsy: a randomized, controlled trial. J Urol. 2009; 181: 585-593.

9. Rojas-Rivera W, Camacho-Aguilar M. Sedación ¿Qué es?, ¿Quien debe administrarla? Acta Med Costarric. 2004; 46: 68 71.

10. Shen P-F, Zhu Y-C, Wei W-R, et al. The results of transperineal versus transrectal prostate biopsy: a systematic review and meta-analysis. Asian J Androl. 2012; 14: 310-315.

11. Walsh K, O'Brien T, Salemmi A, Popert R. Transrectal periprostatic lidocaine injection anesthesia for transrectal prostate biopsy: A prospective study. Prostate Cancer Prostatic Dis. 2003; 6: 311-314.

12. Walsh K, O'Brien T, Salemmi A, Popert R. A randomised trial of periprostatic local anaesthetic for transrectal biopsy. Prostate Cancer Prostatic Dis. 2003; 6: 242-244.

13. Rodríguez A, Kyriakou G, Leray E, Lobel B, Guillé F. Prospective study comparing two methods of anaesthesia for prostate biopsies: Apex periprostatic nerve block versus intraurethral lidocaine gel: Review of the literature. Eur Urol. 2003; 44: 195-200.

14. Addla SK, Adeytoju AAB, Wemys-Holden GD, Neilson D. Local anaesthetic for transrectal ultrasound-guided prostate biopsy: a prospective, randomized, double blind, placebo-controlled study. Eur Urol. 2003; 43: 441-443.

15. Giannarini G, Autorino R, Valent F, et al. Combination of perianal-intrarectal lidocaine-prilocaine cream and periprostatic nerve block for pain control during transrectal ultrasound guided prostate biopsy: a randomized, controlled trial. J Urol. 2009; 181: 585-593.

16. Nazir B. Pain during transrectal ultrasound-guided percutaneous prostate biopsy. Arch Ital Urol Androl. 2004; 76: 114-118.

17. Ashley RA, Inman BA, Routh JC, et al. Preventing pain during office biopsy of the prostate: a single center, prospective, double-blind, 3-arm, parallel group, randomized clinical trial. Cancer. 2007; 110: 1708-1714.

18. O’Reilly PH. Periprostatic nerve block gives better analgesia for prostate biopsy. BJU Int. 2002; 90: 424-426.

19. O’Reilly PH, Collins GN, Brown SCW, Rohlhoff LL. Periprostatic nerve block versus a Lidocaine-Bupivacaine Combination in a Periprostatic Nerve Block Undergoing TransrectalUltrasound Guided Biopsies: Apex periprostatic nerve block: what radiologists should know. Korean J Radiol. 2014; 15: 543-553.

20. Lehman RA, Inman BA, Routh JC, et al. Effect of local anesthetic use. Prostate Cancer Prostatic Dis. 2002; 5: 209-211.

21. Lynn NNK, Collins GN, Brown SCW, O’Reilly PH. Periprostatic nerve block gives better analgesia for prostate biopsy. BJU Int. 2002; 90: 424-426.

22. Kim S, Yoon BI, Kim SJ, et al. Effect of oral administration of acetaminophen and topical application of emla on pain during transrectal ultrasound-guided prostate biopsy. Korean J Urol. 2011; 52: 452-456.

23. Manikandan R, Srirangam SJ, Brown SCW, O’Reilly PH, Collins GN. Nitrous oxide vs periprostatic nerve block with 1% lidocaine during transrectal ultrasound guided biopsy of the prostate: a prospective, randomized, controlled trial. J Urol. 2003; 170: 1881-1883.

24. Obek C, Ozkan B, Tunc B, Can G, Yalcin V, Solok V. Comparison of 3 different methods of anesthesia before transrectal prostate biopsy: a prospective randomized trial. J Urol. 2004; 172: 502-505.

25. Mallick S, Humbert M, Braud F, Fofana M, Blanchet P. Local anesthesia before transrectal ultrasound guided prostate biopsy: comparison of 2 methods in a prospective, randomized clinical trial. J Urol. 2004; 171: 730-733.

26. Vanni AP, Schaal CH, Costa RP, Sala FC. Is the periprostatic anesthetic blockade advantageous in ultrasound-guided prostate biopsy? Int Braz J Urol. 2004; 30: 114-118.

27. Trucchi A, De Nunzio C, Mariani S, Palleschi G, Miano L, Tubaro A. Local anesthesia reduces pain associated with transrectal prostatic biopsy: A prospective randomized study. Urol Int. 2005; 74: 209-213.

28. Kravchick S, Peled R, Ben-Dor D, Dorfman D, Kesari D, Cytron S. Sedación ¿Qué es?, ¿Quien debe administrarla? Acta Med Costarric. 2004; 46: 68 71.
Comparison of different local anesthesia techniques during TRUS-guided biopsies: A prospective pilot study. Urolgy. 2005; 65: 109-113.

32. Ragavan N, Philip J, Balasubramanian SP, Desouza J, Marr C, Javle P. A randomized, controlled trial comparing lidocaine periprostatic nerve block, diclofenac suppository and both for transrectal ultrasound guided biopsy of prostate. J Urol. 2005; 174: 510-513.

33. Feltes Ochoa JA, Passas Martinez J, Felip Santamaria N, Romero Otero J, Rodriguez Antolin A, Leiva Galvis D. Local anesthesia significantly improves the tolerance of prostate biopsy. Arch Esp Urol. 2006; 59: 407-414.

34. Song S-H, Kim JK, Song K, Ahn H, Kim C-S. Effectiveness of local anesthesia techniques in patients undergoing transrectal ultrasound-guided prostate biopsy: a prospective randomized study. Int J Urol. 2006; 13: 707-710.

35. Yun TJ, Lee HJ, Kim SH, Lee SE, Cho JY, Seong CK. Does the intrarectal instillation of lidocaine gel before periprostatic neurovascular bundle block during transrectal ultrasound guided prostate biopsies improve analgesic efficacy? A prospective, randomized trial. J Urol. 2007; 178: 103-106.

36. Izol V, Soyupak B, Seydaoglu G, Aridogan IA, Tansug Z. Three different techniques for administering analgesia during transrectal ultrasound-guided prostate biopsy: A comparative study. Int Braz J Urol. 2012; 38: 122-128.

37. Griwan MS, Kumar A, Sen J, Singh SK. Comparative evaluation of periprostatic nerve block and diclofenac patch in transrectal ultrasound-guided prostate needle biopsy. Nephrourol Mon. 2012; 4: 560-564.

38. Ozok HU, Sagnak L, Ates MA, Karakoyunlu N, Topaloglu H, Ersoy H. The efficiency of a sedative or analgesic supplement to periprostatic nerve blockade for pain control during transrectal ultrasound-guided prostate biopsy - a prospective, randomized, controlled, double blind study. Arch Med Sci. 2010; 6: 787-792.

39. Sataa S, Ramzi M, Mohamed C, et al. Local anesthesia in transrectal ultrasound-guided prostate biopsy: Apical periprostatic nerve block versus endorectal lidocaine gel. A randomized controlled trial about 100 patients. Tunisie Med. 2010; 88: 217-222.

40. Szlauer R, Götschl R, Gnad A, et al. Comparison of lidocaine suppositories and periprostatic nerve block during transrectal prostate biopsy. Urol Int. 2008; 80: 253-256.

41. Raber M, Scattoni V, Roccigno M, et al. Topical Prilocaine-lidocaine cream combined with peripheral nerve block improves pain control in prostatic biopsy: Results from a Prospective Randomized Trial. Eur Urol. 2008; 53: 967-975.

42. Jones JS, Ulchaker JC, Nelson D, et al. Periprostatic local anesthesia eliminates pain of office-based transrectal prostate biopsy. Prostate Cancer Prostatic Dis. 2003; 6: 53-55.

43. Turgut AT, Ergun E, Kosar U, Kosar P, Ozcan A. Sedation as an alternative method to lessen patient discomfort due to transrectal ultrasonography-guided prostate biopsy. Eur J Radiol. 2006; 57: 148-153.

44. Yang L-P, Deng J-H, Zhong H, Hu J-B, Wei H-A, Wang L-S. Transrectal ultrasound guided periprostatic nerve blockade for pain control during transrectal prostate biopsy. Chinese J Cancer Res. 2005; 17: 291-293.

45. Namibrajan T, Woolsey S, Mahendra V, Walsh IK, Lynch TH, Keane PF. Efficacy and safety of peri-prostatic local anaesthetic injection in trans-rectal biopsy of the prostate: A prospective randomised study. Surgenon. 2004; 2: 221-224.

46. Gurbuz C, Canat L, Bayram G, Gokhan A, Samet G, Caskurlu T. Visual pain score during transrectal ultrasound-guided prostate biopsy using no anaesthesia or three different types of local anaesthetic application. Scand J Urol Nephrol. 2010; 44: 212-216.

47. Park SM Roh SH HSJ. The effects of combination of intrarectal lidocaine-gel with periprostatic lidocaine injection on the pain relief in repeated transrectal prostate biopsy. Korean J Urol. 2005; 46: 1051-1056.

48. Bajjar H, Bajjar MM, Ozcan S, Akpinar S, Bajjar H, Battsleam L. Local anesthesia in transrectal ultrasound-guided prostate biopsy: EMLA cream as a new alternative technique. Scand J Urol Nephrol. 2005; 39: 130-134.

49. Cantelli F, Imperatore V, Iannuzzo M, et al. Periprostatic nerve block (PNB) alone vs PNB combined with an anaesthetic-myorelaxant agent cream for prostate biopsy: A prospective, randomized double-arm study. BJU Int. 2009; 103: 1195-1198.

50. Anup K, Pawan V, Niran K, Biswajit N, Nayan MK. A prospective randomized trial comparing three different analgesic techniques for pain control during transrectal ultrasound guided prostate biopsy: A single centre experience. Minerva Urol Nefrol. 201; 65: 77-82.

51. Dalıa I, Akan H, Yildiz O, Sarısahin M. Combination of perianal EMLA cream and periprostatic nerve block for pain control during trus-guided prostate biopsy. Urology. 2013; 82 (3 Suppl. 1): 265-266.

52. Wu CL, Carter HB, Naqibuddin M, Fleisher LA. Effect of local anesthetics on patient recovery after transrectal biopsy. Urology. 2001; 57: 925-929.

53. Rodriguez A, Tazi H, Kyriakou G, Leray E, Lobel B, Gullé F. Peri-prostatic nerve block at the level of the apex versus intrarectal lidocaine gel. Prog Urol. 2002; 12: 1228-1233.

54. Lunacek A, Mrštik C, Simon J, et al. Combination of lidocaine suppository and periprostatic nerve block during transrectal prostate biopsy: A prospective randomized trial. Int J Urol. 2014; 21: 1126-1130.

55. Damiano R, Cantiello F, Sacco R, Autorino R, de Sio M, D’Armento M. Randomized placebo-controlled study of periprostatic local anesthetic for transrectal ultrasound-guided prostate biopsy. Arch Ital Urol Androl. 2004; 76: 163-166.

56. Song S, Ji Y, Lee S, et al. A Prospective Randomized Study Comparing Effectiveness of Local Anesthesia Techniques in Patients undergoing Transrectal Ultrasound-guided Prostate Biopsy. Korean J Urol. 2004; 45: 236-239.

57. Yun T, Lee H, Kim S, Lee S, et al. Analgesic Efficacy of Intrarectal Instillation of Lidocaine Gel prior to Transrectal Ultrasound Guided Prostate Biopsy: A Prospective Randomized Trial. J Korean Soc Ultrasound Med. 2006; 25: 81-85.

58. Ingber MS, Ibrahim I, Turzewski C, Hollander JB, Diokno AC. Does periprostatic block reduce pain during transrectal prostate biopsy? A randomized, placebo-controlled, double-blinded study. Int Urol Nephrol. 2010; 42: 23-27.